Skip to main content
. Author manuscript; available in PMC: 2015 Jun 5.
Published in final edited form as: Mol Cell. 2014 May 22;54(5):777–790. doi: 10.1016/j.molcel.2014.04.025

Figure 3. LincRNA-p21 regulates PRC2 target genes through p21.

Figure 3

(A) Bar plot of normalized RNA levels of selected lincRNA-p21-regulated, PRC2 target genes in indicated cells, analyzed by qRT-PCR. Data are represented as mean±SEM, n=3.

(B) ChIP-qPCR analysis of the enrichment of H3K4me3 (left) and H3K27me3 (right) at the promoters of the indicated genes in doxorubicin-treated MEFs. Data, replicated in 2 independent experiments, are represented as mean±SEM of technical replicates.

(C) qRT-PCR analysis of lincRNA-p21 (left) and p21 (right) in a lincRNA-p21f/f; CreERT2 MEF line, infected with p21- or control luciferase (L)-specific shRNAs, harvested at 96 hours following mock treatment or tamoxifen (Tam)-mediated deletion of lincRNA-p21 and at 24 hours following mock treatment or doxorubicin (Doxo)-induced DNA damage. Data are represented as mean±SEM of technical replicates.

(D) qRT-PCR analysis of the effects of the treatments described in (C) on the expression levels of indicated lincRNA-p21-regulated, PRC2 target genes. Data were confirmed with an independent p21-targeting shRNA (not shown). See also Figure S5 and Table S4.